

## Sun Pharma Advanced Research Company Limited

Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway,  
Manjusar, Vadodara – 391 775. Tel. : +91-2667 666800  
CIN : L73100GJ2006PLC047837. Website : www.sparc.life

### Statement of Unaudited Financial Results for the Quarter Ended June 30, 2021

Particulars	Quarter ended			Year ended
	30.06.2021	31.03.2021	30.06.2020	31.03.2021
	Unaudited	Audited	Unaudited	Audited
		(Refer Note 6)		
Revenue from operations	2,199	2,806	18,545	25,296
Other income	80	33	66	541
<b>Total income</b>	<b>2,279</b>	<b>2,839</b>	<b>18,611</b>	<b>25,837</b>
<b>Expenses</b>				
Cost of materials consumed	287	218	624	1,818
Employee benefits expense	2,552	2,210	2,400	9,158
Clinical trial expenses / products development expense	2,470	3,403	6,289	18,823
Professional charges	1,490	1,150	1,649	4,972
Finance costs	537	402	197	1,065
Depreciation and amortisation expense	253	260	278	1,092
License and fees	98	79	783	945
Other expense	729	789	722	3,078
<b>Total expenses</b>	<b>8,416</b>	<b>8,511</b>	<b>12,942</b>	<b>40,951</b>
<b>Profit / (loss) before tax</b>	<b>(6,137)</b>	<b>(5,672)</b>	<b>5,669</b>	<b>(15,114)</b>
Tax expense	-	-	-	-
<b>Profit / (loss) for the period</b>	<b>(6,137)</b>	<b>(5,672)</b>	<b>5,669</b>	<b>(15,114)</b>
<b>Other comprehensive income / (loss) (OCI)</b>				
Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on	38	350	(66)	153
<b>Total comprehensive income / (loss) for the period</b>	<b>(6,099)</b>	<b>(5,322)</b>	<b>5,603</b>	<b>(14,961)</b>
Paid-up equity share capital (Face value Rs. 1 each)	2,621	2,621	2,621	2,621
Other equity				(19,446)
Basic and diluted earnings per share of Rs. 1 each	(2.34)	(2.16)	2.16	(5.77)
	Not annualised	Not annualised	Not annualised	
<i>See accompanying notes to the financial results</i>				

#### Notes :

- 1 The above unaudited financial results have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on July 26, 2021 after being reviewed by the Audit Committee and have been subjected to a limited review by Statutory Auditors of the Company.
- 2 The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.
- 3 On July 08, 2021, the Company has allotted 6,24,74,082 warrants, each convertible into one equity share, on preferential basis at an issue price of Rs. 178/- each, upon receipt of 25% of the issue price (i.e. Rs. 44.50 per warrant) as warrant subscription money. Balance 75% of the issue price (i.e. Rs. 133.50 per warrant) shall be payable within 18 months from the allotment date, at the time of exercising the option to apply for fully paid-up equity share of Rs. 1/- each of the Company, against each warrant held by the warrant holder.
- 4 The global wide spread of COVID-19 has been a fluid and challenging situation facing all the industries. The Company has taken all possible effective measures to limit and keep the impact of COVID-19 under control in order to ensure business continuity with minimal disruption. The Company has considered internal and external information while finalizing various estimates in relation to its audited financial results captions upto the date of approval of the audited financial results by the Board of Directors. The Company continues to pay close attention to the development of COVID-19, and will further evaluate and actively respond to such impact on the financial position and financial performance of the Company.
- 5 The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the subsequent financial results when the Rules/Schemes thereunder are notified.
- 6 The figures of the last quarters are the balancing figures between audited figures in respect of the full previous financial year up to March 31, 2021 and the unaudited published year-to-date figures up to December 31, 2020, being the date of the end of the third quarter of the financial years which were subjected to limited review.
- 7 Previous period figures have been regrouped / rearranged, wherever necessary.

By order of the Board

Dilip S. Shanghvi  
Chairman

Mumbai, July 26, 2021